Announcements and developments from the Brain Science Institute and brain science community.
JHU and the Institute of Organic Chemistry and Biochemistry Enter Partnership
The Johns Hopkins Drug Discovery (JHDD) program, created with the mission of identifying novel drug targets arising from Johns Hopkins faculty research and translating them into new therapeutics, and the Institute of Organic Chemistry and Biochemistry , The Czech Academy of Sciences (IOCB Prague) have entered into a five-year drug discovery research agreement to develop small-molecule and peptide drugs for a range of therapeutic areas including neurological diseases, cancer, and gastrointestinal disorders. Johns Hopkins Brain Science Institute Hosts Conference to Explore New Paradigm for Drug Discovery
Industry and Academia Leaders Seek Solutions at Oct. 18 Symposium
A symposium to be hosted by the Johns Hopkins Brain Science Institute (BSi) on Oct. 18 at the Baltimore Convention Center will bring together the pharmaceutical industry and academic-based research institutions with the common goal of exploring how the two can best work together to enhance and facilitate the discovery of new drugs. In Memoriam: John W Griffin MD
It is with a profound sense of loss that we announce the death of John Griffin, an internationally acclaimed and admired expert on diseases of the peripheral nervous system. Known affectionately to all as Jack, he served as the founding director of the Johns Hopkins Brain Science Institute from 2007 until just earlier this month, and was a former director of the Department of Neurology. He died on Saturday, April 16, at the age of 69. BSi Forges Agreement to Develop Novel Therapeutics for Neurological and Psychiatric Disorders
January 2011. The Johns Hopkins Brain Science Institute (BSi) announced today that it has entered into an agreement with Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI) to advance the development of novel therapeutics for neurological and psychiatric diseases. BSi Funds Research Initiatives to Launch New “Synapses, Circuits and Cognitive Disorders” Program
January 2011. Johns Hopkins University School of Medicine’s Brain Science Institute has just announced the funding of grants totaling 5 million dollars over a two-year period to launch its new Synapses, Circuits and Cognitive Disorders Program. Twelve grants were funded out of 28 applications. The awards were given to individual and collaborative investigators in 12 different Departments in 4 Schools throughout the University. These grants will advance the BSi goal to address the fundamental role of synapses in brain function at the molecular, cellular or systems level as well as address the mechanisms underlying cognitive disorders such as Alzheimer’s disease, schizophrenia and autism. The Science of the Arts
Johns Hopkins Brain Science Institute Launches Public Lecture Series on Sensory Science and the Arts BSi Supports Neuroscience Researchers and Their Innovative Studies
In this period of tighter research support by the NIH and other government agencies, some of the most innovative and potentially important ongoing research projects can have funding interrupted. To respond to this problem, the Brain Science Institute (BSi) developed the Sustaining Innovation in the Neurosciences (SIN) program. Brain Science Institute Announces License Agreement to Develop Treatments for Neurological Disease
Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors. BSi Releases Progress Report – November 2009
We are pleased to announce the first BSi Progress Report sharing our vision, accomplishments and history. BSi’s Newest Grant Recipients Stand Out for Breadth, Innovation
Hopkins’ Brain Science Institute has just announced its second cycle of research grants, awards totaling $6.4 million over a two-year period. The 16 grants extend to research teams throughout the university’s schools and campuses, advancing the BSI goal to solve fundamental questions of brain development and function and translate those findings into therapy. New Hopkins Imaging Center to Widen Windows on the Brain
It’s a classic academic mismatch: Researchers aren’t able to make use of seminal improvements in technology – often from colleagues just across the street – either because they don’t know about them or because gaining familiarity makes unrealistic demands on their time. For those very reasons, Hopkins’ Brain Science Institute is underwriting the Center for Brain Imaging (CBI). BSi Announces Collaboration with Biogen to Develop New Treatments for Brain Disorders
Johns Hopkins University’s newly formed Brain Science Institute (BSI) and pharmaceutical development company Biogen Idec have agreed to collaborate on the development of new therapies for such neurodegenerative diseases as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease. BSi presents: Biotech 2008 Neuroscience Investors Conference: Investing in Brain Research
More than 20 world-renowned scientists and industry leaders presenting the current state of neurobiology research and discussing challenges of speeding drug discovery for brain diseases to an audience of more than 200 research scientists, leaders in the pharmaceutical and biotechnology industries, business development executives, venture capitalists, investment bankers, and consulting and legal service providers. MRI vertigo caused by the magnetic field affecting fluid in the inner ear
Machine’s magnetic field pushes fluid in the inner ear’s balance organ.
A team of researchers says it has discovered why so many people undergoing magnetic resonance imaging (MRI), especially in newer high-strength machines, get vertigo, or the dizzy sensation of free-falling, while inside or when coming out of the tunnel-like machine.